This company listing is no longer active
DNL Stock Overview
Diurnal Group plc operates as a specialty pharma company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Diurnal Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.27 |
| 52 Week High | UK£0.68 |
| 52 Week Low | UK£0.095 |
| Beta | 0.35 |
| 1 Month Change | 0.55% |
| 3 Month Change | 180.00% |
| 1 Year Change | -54.65% |
| 3 Year Change | -14.69% |
| 5 Year Change | -80.84% |
| Change since IPO | -82.16% |
Recent News & Updates
Recent updates
Diurnal Group (LON:DNL) Will Have To Spend Its Cash Wisely
Aug 13
Shareholders May Not Be So Generous With Diurnal Group plc's (LON:DNL) CEO Compensation And Here's Why
Nov 13Companies Like Diurnal Group (LON:DNL) Can Afford To Invest In Growth
Feb 25What Can We Learn About Diurnal Group's (LON:DNL) CEO Compensation?
Feb 04Diurnal Group plc (LON:DNL): When Will It Breakeven?
Jan 14Diurnal Group (LON:DNL) Shareholders Have Enjoyed A 88% Share Price Gain
Dec 25Estimating The Fair Value Of Diurnal Group plc (LON:DNL)
Dec 02Shareholder Returns
| DNL | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | 2.2% |
| 1Y | -54.7% | -29.1% | 0.9% |
Return vs Industry: DNL underperformed the UK Biotechs industry which returned -42.3% over the past year.
Return vs Market: DNL underperformed the UK Market which returned -13.8% over the past year.
Price Volatility
| DNL volatility | |
|---|---|
| DNL Average Weekly Movement | 38.5% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: DNL's share price has been volatile over the past 3 months.
Volatility Over Time: DNL's weekly volatility has increased from 21% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Richard Bungay | www.diurnal.co.uk |
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency.
Diurnal Group plc Fundamentals Summary
| DNL fundamental statistics | |
|---|---|
| Market cap | UK£47.74m |
| Earnings (TTM) | -UK£16.57m |
| Revenue (TTM) | UK£4.68m |
10.2x
P/S Ratio-2.9x
P/E RatioIs DNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DNL income statement (TTM) | |
|---|---|
| Revenue | UK£4.68m |
| Cost of Revenue | UK£1.02m |
| Gross Profit | UK£3.66m |
| Other Expenses | UK£20.23m |
| Earnings | -UK£16.57m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.095 |
| Gross Margin | 78.16% |
| Net Profit Margin | -353.76% |
| Debt/Equity Ratio | 0.0% |
How did DNL perform over the long term?
See historical performance and comparison